Pancreatic cancer
Incidence and mortality
Deaths annually increasing
Risk factors
Types and stage
Early detection
Carbohydrate antigen 19-9
Glypican-1 positive exosomes
Carcinogenesis
Early stage disease
Neoantigen qualities
Cancer treatment
Immune checkpoint blockade
Novel immune therapies
Genetic alterations
Precision medicine
iExosomes
Complex microenvironment
Desmoplastic stroma
Cancer associated fibroblasts
Tumor heterogeneity
PDAC subtypes
Classical subtype
Chromosome structure
Stroma specific subtypes
Metabolic reprogramming
Stellate cells
RAS/MAPK
Trametinib plus HCQ
Drug delivery
Mouse model
Stroma targeting
Therapeutic response
Phase II trial
Hedgehog signaling
Tumor suppressor
Myoblast depletion
Overall survival
Anti-stromal therapy
Mesothelin
MSLN expression
MSLN threapeutics
Recombinant immunotoxin
Mechanism of action
LMB-100 plus paclitaxel
Active regimen
Anti-drug antibody
Decreasing ADA
Tofacitinib
Tocacitinib + LMB-100
Questions?
